Browsing Tag
CAR-T therapy
19 posts
Can parallel CAR-T targeting finally solve relapse in multiple myeloma
Can dual-targeting CAR-T solve relapse in multiple myeloma? Explore how Tempest Therapeutics, Inc. is positioning TPST-2003 for next-gen impact.
A one-time lupus reset? Why CTA313 is forcing competitors to rethink strategy
Can CTA313 disrupt lupus markets with one-time remission? Explore how Imviva Biotech is reshaping autoimmune competition.
How tetrahedral antibody design may improve efficacy and safety in immune-mediated diseases
Biomolecular Holdings LLC patents tetrahedral antibodies. Discover how this design could reshape efficacy and safety in immune-mediated diseases.
Is TPST-2003’s early efficacy enough to disrupt the current CAR-T landscape in multiple myeloma
Can TPST-2003 disrupt CAR-T therapy in multiple myeloma? Explore what Tempest Therapeutics, Inc.’s strategy means for investors and the industry.
Glioblastoma trial for MT027 moves forward as T-MAXIMUM debuts allogeneic cell therapy in CNS
T-MAXIMUM wins FDA clearance for MT027 in glioblastoma. Read how its non-viral, off-the-shelf CAR-T may reshape solid tumor cell therapy development.
Is Vivacta Bio’s GT801 the next frontier in CAR-T therapy? Early human data reveal scalable, chemo-free promise
Vivacta Bio’s GT801 shows early promise as a repeat-dose in vivo CAR-T therapy for lymphoma. Find out how this could reshape immunotherapy delivery.
Is Johnson & Johnson’s CARVYKTI shifting the multiple myeloma treatment curve?
Johnson & Johnson’s CARVYKTI shows 80% 30-month remission in earlier-line multiple myeloma. See how CARTITUDE-4 could change the treatment landscape.
Why Imugene is using a virus to “mark” tumors for CAR-T attack—and what JW Therapeutics brings to the table
Find out how Imugene and JW Therapeutics plan to make solid tumors respond to CD19 CAR-T therapy using an oncolytic virus strategy.
Cabaletta Bio’s rese-cel CAR-T data at ESGCT 2025 reveal biologic activity without preconditioning in autoimmune disease
Cabaletta Bio’s ESGCT 2025 rese-cel data show early CAR-T activity without chemotherapy preconditioning — see how this could redefine autoimmune therapy.
Can immune-based doublets push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
Can immune-based doublets like TECVAYLI and DARZALEX FASPRO push CAR-T and bispecifics into earlier multiple myeloma treatment lines?